Strong revenue performance ahead of further country launches in Europe. ·Cash position at 31 December 2019: £4.6 m before an outstanding R&D tax credit claim of £2.1 m in respect of 2019 financial year which the company expects to receive during 2020. ·Alkindi ® now launched in UK, Germany, Austria, Sweden, Norway, Denmark and Iceland, with further launches...
RNS Number: 5147 Z Diurnal Group PLC 13 January 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5148 Z Diurnal Group PLC 13 January 2020 13 January 2020. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. RNS is approved by the Financial...
Peter Allen, Chairman, exercised an option to acquire 173,421 new ordinary shares of £0.05 each at a price of £0.002 per Ordinary Share and acquired 70,500 Ordinary Shares at a price of 28.4 pence per Ordinary Share. He also acquired 35,211 Ordinary Shares at a price of 28.4 pence per Ordinary Share.. Additionally, for tax planning purposes, John Goddard sold...
On 10 January 2020, Diurnal issued a total of 1,214,660 par value options over ordinary shares of 5 pence in the Company under the Diurnal Group plc Long Term Incentive Plan, of which the following were issued to persons discharging managerial responsibilities:. ·Achieving a target share price of 89 pence for a one-month rolling period during the 5 years...
Martin Whitaker, Chief Executive Officer, purchased 25,000 Ordinary Shares at a price of 30 pence per Ordinary Share. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal...
Chronocort ® Marketing Authorisation Application Submitted in Europe. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that, in line with expectations, a Market Authorisation Application has been submitted to the European Medicines Agency for Chronocort ® as a treatment for...
RNS Number: 3740 V Diurnal Group PLC 02 December 2019 2 December 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that it has issued 30,000 new ordinary shares of 5 pence each as a result of an exercise of options under the Company's Long Term Incentive Plan.. Founded in 2004, Diurnal...
RNS Number: 2374 V Diurnal Group PLC 02 December 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2373 V Diurnal Group PLC 02 December 2019 02 December 2019. US submission follows successful launch in Europe. The pathway is based on a development programme for Alkindi ®, including a study to demonstrate bioequivalence with the US reference product, as well as a safety evaluation and tolerability extension study in Europe, which provides...
End of Announcement- EQS News Service.
RNS Number: 2482 U Diurnal Group PLC 21 November 2019 21 November 2019. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. RNS is approved by the Financial...
Diurnal's primary focus remains on progressing Chronocort ® and Alkindi ®, our two lead products, which are potentially valuable treatment options with a combined opportunity of over $3 bn for diseases resulting from cortisol deficiency in the US and Europe.. Diurnal remains on track to submit two key regulatory filings during Q4 2019, namely a Marketing...
RNS Number: 9755 T Diurnal Group PLC 20 November 2019 20 November 2019. Potential to be the first effective oral native testosterone treatment in a $4.8 bn global market. The estimated $4.8 billion market in US and Europe for testosterone-based products for the treatment of hypogonadism is dominated by topically-available products, which have compliance...
Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that the Remuneration Committee has determined the proportion of options over ordinary shares of 5 pence each in Diurnal previously granted under the Diurnal Group plc Long Term Incentive Plan to Directors of the Company that are...
End of Announcement- EQS News Service.
RNS Number: 6211 Q Diurnal Group PLC 21 October 2019 21 October 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that further to the Directors' dealings announced today, the new Ordinary Shares were issued from the Company's Employee Benefit Trust scheme. 1,786,439 new Ordinary...
RNS Number: 5835 Q Diurnal Group PLC 21 October 2019 21 October 2019. Martin Whitaker, Chief Executive Officer, exercised options over 424,500 ordinary shares of £0.05 each at a price of 0.2 p pence per Ordinary Share and sold 230,152 Ordinary Shares at a price of 26 pence per ordinary share in order to fund the exercise price, income taxes, and to satisfy market...
The Company's AGM will be held at 11.00 am at the offices of FTI Consulting LLP, 200 Aldersgate, Aldersgate Street, London, EC1A 4 HD on Thursday 21 November 2019.. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including...
